| 1 |
31355228 |
10.21037/atm.2019.05.28 |
2022 |
Prognostic significance of the <i>PANK</i> family expression in acute myeloid leukemia. |
MET |
| 2 |
31576173 |
10.2147/CMAR.S194337 |
2022 |
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma. |
MET |
| 3 |
31749998 |
10.1136/bmjgh-2019-001825 |
2022 |
Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review. |
MET |
| 4 |
31807491 |
10.4103/sajc.sajc_373_18 |
2022 |
Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association. |
MET |
| 5 |
32346306 |
10.2147/IJGM.S245779 |
2022 |
Patterns of Glucose Fluctuation are Challenging in Patients Treated for Non-Hodgkin's Lymphoma. |
MET |
| 6 |
32408414 |
10.5045/br.2020.2020032 |
2022 |
Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma. |
MET |
| 7 |
32457620 |
10.3389/fphar.2020.00621 |
2022 |
Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System. |
MET |
| 8 |
32577090 |
10.6001/actamedica.v27i1.4260 |
2022 |
Improvement in childhood cancer survival in Lithuania over three decades. |
MET |
| 9 |
32606772 |
10.2147/OTT.S250233 |
2022 |
HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice. |
MET |
| 10 |
32656132 |
10.4103/ajns.AJNS_366_19 |
2022 |
Radiologic-Histopathologic Correlation of Adult Spinal Tumors: A Retrospective Study. |
MET |
| 11 |
32661506 |
10.15344/2456-8007/2020/145 |
2022 |
Prevalence of Malignancy Among Urban Black Rheumatoid Arthritis Patients. |
MET |
| 12 |
33043062 |
10.36469/jheor.2020.17088 |
2022 |
Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. |
MET |
| 13 |
33094130 |
10.14338/IJPT-20-00010.1 |
2022 |
Reducing Heart Dose with Protons and Cardiac Substructure Sparing for Mediastinal Lymphoma Treatment. |
MET |
| 14 |
33145207 |
10.4103/ajns.AJNS_208_20 |
2022 |
Outcome and Prognostic Factors of Primary Central Nervous System Lymphoma in Southern Thailand. |
MET |
| 15 |
33402590 |
10.4103/ijc.IJC_470_19 |
2022 |
FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience. |
MET |
| 16 |
33423957 |
10.1016/j.jasc.2020.12.002 |
2022 |
Oncogenic gene transcripts detection by FISH on liquid-based cytology slides of 338 advanced lung cancer patients. |
MET |
| 17 |
33487576 |
10.1016/j.clml.2020.12.015 |
2022 |
Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria. |
MET |
| 18 |
33537137 |
10.1016/j.amsu.2021.01.059 |
2022 |
A case series of hilar cholangiocarcinoma: A single surgeon experience over 20-years. |
MET |
| 19 |
33632668 |
10.1016/j.clml.2020.12.012 |
2022 |
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. |
MET |
| 20 |
33660798 |
10.26355/eurrev_202102_25083 |
2022 |
Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. |
MET |
| 21 |
33685866 |
10.1158/1078-0432.CCR-21-0032 |
2022 |
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. |
MET |
| 22 |
33776456 |
10.2147/IDR.S295077 |
2022 |
The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma. |
MET |
| 23 |
33889527 |
10.21037/tlcr-21-160 |
2022 |
Concomitant mutation status of <i>ALK</i>-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. |
MET |
| 24 |
33889528 |
10.21037/tlcr-20-1113 |
2022 |
A narrative review of MET inhibitors in non-small cell lung cancer with <i>MET</i> exon 14 skipping mutations. |
MET |
| 25 |
33898318 |
10.3389/fonc.2021.647598 |
2022 |
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients. |
MET |
| 26 |
33951890 |
10.3324/haematol.2021.278311 |
2022 |
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. |
MET |
| 27 |
33952592 |
10.1136/jclinpath-2021-207597 |
2022 |
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. |
MET |
| 28 |
33977256 |
10.1002/iju5.12279 |
2022 |
Rare case of immunoglobulin G4-related disease arising in gonadal glands with long-term remission without steroid treatment: Discussion and literature review. |
MET |
| 29 |
34003566 |
10.1002/pbc.29141 |
2022 |
Phase-specific risks of outpatient visits, emergency visits, and hospitalizations during Children's Oncology Group-based treatment for childhood acute lymphoblastic leukemia: A population-based study. |
MET |
| 30 |
34011485 |
10.1016/j.clml.2021.04.003 |
2022 |
The Pattern of Use of PET/CT Scans in the Clinical Management of Chronic Lymphocytic Leukemia. |
MET |
| 31 |
34031277 |
10.5045/br.2021.2021028 |
2022 |
Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma. |
MET |
| 32 |
34045224 |
10.1136/bmjspcare-2020-002532 |
2022 |
Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis. |
MET |
| 33 |
34052119 |
10.1016/j.oraloncology.2021.105351 |
2022 |
Solitary extramedullary plasmacytoma of the nasopharynx: The role of flow cytometry. |
MET |
| 34 |
34058070 |
10.1002/1878-0261.13033 |
2022 |
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. |
MET |
| 35 |
34059475 |
10.1016/j.cllc.2021.04.008 |
2022 |
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib. |
MET |
| 36 |
34110383 |
10.1001/jamaoncol.2021.1649 |
2022 |
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. |
MET |
| 37 |
34137303 |
10.1177/00034894211025171 |
2022 |
Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival. |
MET |
| 38 |
34214988 |
10.3171/2020.12.JNS202517 |
2022 |
Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma. |
MET |
| 39 |
34274491 |
10.1016/j.jtct.2021.07.010 |
2022 |
A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. |
MET |
| 40 |
34313176 |
10.1080/10428194.2021.1957868 |
2022 |
Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome. |
MET |
| 41 |
34321836 |
10.21147/j.issn.1000-9604.2021.03.11 |
2022 |
Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma. |
MET |
| 42 |
34326171 |
10.1136/jitc-2021-002968 |
2022 |
Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. |
MET |
| 43 |
34336635 |
10.3389/fonc.2021.609882 |
2022 |
Primary Diffuse Large B-Cell Lymphoma of the Urinary Tract: A Population-Based Analysis. |
MET |
| 44 |
34409369 |
10.1016/j.jdin.2021.01.002 |
2022 |
Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review. |
MET |
| 45 |
34410295 |
10.1001/jamaoncol.2021.2723 |
2022 |
Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. |
MET |
| 46 |
34438277 |
10.1016/j.jchromb.2021.122905 |
2022 |
A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography/tandem mass spectrometry. |
MET |
| 47 |
34464024 |
10.1111/vco.12768 |
2022 |
Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. |
MET |
| 48 |
34465277 |
10.2174/0929867328666210831142311 |
2022 |
The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy. |
MET |
| 49 |
34476905 |
10.1002/jmrs.540 |
2022 |
A scoping review of patient selection methods for proton therapy. |
MET |
| 50 |
34486541 |
10.1097/MPH.0000000000002301 |
2022 |
Pulmonary Outcomes After Autologous Stem Cell Transplant for Hodgkin Lymphoma. |
MET |
| 51 |
34490598 |
10.1007/s12185-021-03217-4 |
2022 |
A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation. |
MET |
| 52 |
34541785 |
10.1111/jcmm.16897 |
2022 |
Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. |
MET |
| 53 |
34562212 |
10.1007/s11356-021-16616-1 |
2022 |
Physalis pubescens L. alleviates testicular disruptions associated with streptozotocin-induced diabetes in male Wistar rats, Rattus norvegicus. |
MET |
| 54 |
34587856 |
10.1080/10428194.2021.1984460 |
2022 |
Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. |
MET |
| 55 |
34591804 |
10.1097/INF.0000000000003312 |
2022 |
Initial Seronegative West Nile Virus Encephalitis in an Immunocompromised Child. |
MET |
| 56 |
34595671 |
10.1007/s40273-021-01089-4 |
2022 |
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review. |
MET |
| 57 |
34599665 |
10.1007/s00520-021-06588-w |
2022 |
Physical activity levels, exercise preferences, and exercise barriers in Korean children and adolescents after cancer treatment. |
MET |
| 58 |
34617607 |
10.1111/jsap.13438 |
2022 |
Diagnostic accuracy of ultrasonography to detect hepatic and splenic lymphomatous infiltration in dogs and cats. |
MET |
| 59 |
34632935 |
10.1080/10428194.2021.1986217 |
2022 |
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. |
MET |
| 60 |
34648216 |
10.1002/pbc.29387 |
2022 |
Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia. |
MET |
| 61 |
34651428 |
10.1111/jcmm.16953 |
2022 |
Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma. |
MET |
| 62 |
34686712 |
10.1038/s41598-021-00309-3 |
2022 |
Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. |
MET |
| 63 |
34696815 |
10.1186/s40360-021-00529-3 |
2022 |
High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study. |
MET |
| 64 |
34702929 |
10.1038/s41598-021-00746-0 |
2022 |
Prognostic efficacy of the RTN1 gene in patients with diffuse large B-cell lymphoma. |
MET |
| 65 |
34757015 |
10.1016/j.jmoldx.2021.10.001 |
2022 |
Advanced Minimal Residual Disease Monitoring for Acute Lymphoblastic Leukemia with Multiplex Mediator Probe PCR. |
MET |
| 66 |
34796780 |
10.1080/10408444.2021.1997911 |
2022 |
Using the Matrix to bridge the epidemiology/risk assessment gap: a case study of 2,4-D. |
MET |
| 67 |
34798339 |
10.1016/j.wneu.2021.11.042 |
2022 |
Contiguous Meningioma and B-Cell Lymphoma: A Scoping Review and Case Illustration. |
MET |
| 68 |
34805720 |
10.1177/2473974X211059081 |
2022 |
<sup>18</sup>FDG-PET/CT Specificity for the Detection of Lymphoma Recurrence in the Tonsils. |
MET |
| 69 |
34826411 |
10.1016/S2352-3026(21)00307-0 |
2022 |
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. |
MET |
| 70 |
34838280 |
10.1016/j.jval.2021.06.012 |
2022 |
Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov. |
MET |
| 71 |
34843129 |
10.1111/his.14603 |
2022 |
ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney. |
MET |
| 72 |
34854541 |
10.1002/pbc.29437 |
2022 |
Prevalence of hearing screening failures in low-risk childhood cancer survivors. |
MET |
| 73 |
34862665 |
10.1111/ejh.13728 |
2022 |
Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma. |
MET |
| 74 |
34921238 |
10.1038/s41591-021-01622-0 |
2022 |
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. |
MET |
| 75 |
34980267 |
10.1186/s41043-021-00280-9 |
2022 |
Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis. |
MET |
| 76 |
34987411 |
10.3389/fphar.2021.809467 |
2022 |
Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report. |
MET |
| 77 |
34994987 |
10.1002/14651858.CD013453.pub2 |
2022 |
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer. |
MET |
| 78 |
34999675 |
|
2022 |
A Study on Clinical Presentation and Histological Diagnosis of Lymphadenopathy Patients Admitted In Department of Medicine in A Tertiary Hospital. |
MET |
| 79 |
35003359 |
10.7150/jca.63003 |
2022 |
PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. |
MET |
| 80 |
35007777 |
10.1016/j.tcam.2021.100622 |
2022 |
Retrospective Study of Canine Peripheral Lymphadenopathy in a Mediterranean Region: 130 Cases. |
MET |
| 81 |
35012520 |
10.1186/s12890-021-01803-0 |
2022 |
Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. |
MET |
| 82 |
35017140 |
|
2022 |
Primary Enteric Adenocarcinoma Lung with Mesenchymal Epithelial Transition Factor Amplification: A Case Report. |
MET |
| 83 |
35018520 |
10.1007/s00520-022-06818-9 |
2022 |
Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population. |
MET |
| 84 |
35045791 |
10.1080/10428194.2021.2024817 |
2022 |
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. |
MET |
| 85 |
35102119 |
10.1097/BRS.0000000000004327 |
2022 |
Patient Reported Outcomes in Metastatic Spine Disease: Concurrent Validity of PROMIS with the Spine Oncology Study Group Outcome Questionnaire. |
MET |
| 86 |
35116617 |
10.21037/tcr-20-3473 |
2022 |
Complex genetic alterations contribute to rapid disease progression in an <i>ALK</i> rearrangement lung adenocarcinoma patient: a case report. |
MET |
| 87 |
35116684 |
10.21037/tcr-21-642 |
2022 |
Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report. |
MET |
| 88 |
35120432 |
10.1080/10428194.2021.2024818 |
2022 |
High-dose methotrexate dosing strategy in primary central nervous system lymphoma. |
MET |
| 89 |
35123117 |
10.1016/j.jtct.2022.01.024 |
2022 |
Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis. |
MET |
| 90 |
35123209 |
10.1016/j.esmoop.2021.100337 |
2022 |
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. |
MET |
| 91 |
35125312 |
10.1016/j.iccn.2021.103187 |
2022 |
Symptom experiences of critically-ill hematologic malignancy patients: A scoping review. |
MET |
| 92 |
35133455 |
10.1007/s00404-022-06410-w |
2022 |
Increased incidence of childhood lymphoma in children with a history of small for gestational age at birth. |
MET |
| 93 |
35133871 |
10.1200/JCO.21.01648 |
2022 |
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. |
MET |
| 94 |
35136485 |
10.18632/oncotarget.28189 |
2022 |
GZ17-6.02 and axitinib interact to kill renal carcinoma cells. |
MET |
| 95 |
35149250 |
10.1016/j.wneu.2022.02.015 |
2022 |
Computed Tomography Hounsfield Units as a Predictor of Reoperation and Graft Subsidence After Standalone and Multilevel Lateral Lumbar Interbody Fusion. |
MET |
| 96 |
35171109 |
10.2196/32826 |
2022 |
Mobile Apps for Hematological Conditions: Review and Content Analysis Using the Mobile App Rating Scale. |
MET |
| 97 |
35182296 |
10.1007/s11864-021-00925-1 |
2022 |
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. |
MET |
| 98 |
35184940 |
10.1016/j.semcdb.2022.02.007 |
2022 |
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer. |
MET |
| 99 |
35198656 |
10.1016/j.ejro.2022.100400 |
2022 |
Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis. |
MET |
| 100 |
35198835 |
10.1016/j.adro.2021.100888 |
2022 |
Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials. |
MET |
Datasets
Models
